FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3034172868> ?p ?o ?g. }

• W3034172868 abstract "Abstract Background and Aims Acquired thrombotic thrombocytopenic purpura (aTTP) is a thrombotic microangiopathy still nowadays associated with a high risk of death. Standards of care included at first the association of plasmatic exchanges, Rituximab and steroids. The emergence of Caplacizumab, a nanobody targeting the A1 receptor of Von Willebrand Factor (VWF), significantly changed the prognosis of the disease. Thrombocytopenia is frequent in HIV positive patients, and aTTP is frequently considered. Prevalence of HIV positive in aTTP patients ranges from less than 1% in western countries, up to more than 50% in African countries. The pathophysiology still remains partially understood, leading to the development of autoantibodies targeting the ADAMTS13 metalloprotease. For now, no specific recommendations are available, and standards of care consist in treating HIV positive patient the same as other aTTP patients. We present the first description of two HIV positive patients, successfully treated with caplacizumab. Method We report there two cases of black women, respectively aged 31 (Patient 1) and 52 years old (Patient 2), both positive for HIV for several years. The first one had stopped any antiviral treatment few months ago, and had a positive blood viral load of 110764 copies/ml. Her CD4+ rate was 30/mm3. The second one was under antiviral medication, with a negative viral load and a CD4+ rate of 295/mm3. Both were admitted in our department because of low platelet levels and hemolysis, associated with inflammatory triggers. Bacteriema for Streptococcus mitis was discovered on admission in Patient 1 and Patient 2, who had a long-term follow-up for Still disease, presented with a flare-up. Results Both patients had positive anti-ADAMTS13 autoantibodies (Patient 1: titer 42 UI/ml, Patient 2: 45 UI/ml), with undetectable ADAMTS-13 activities. They were treated with plasmatic exchanges until platelets levels reached over 150 G/L, steroids 1.5 mg/kg/j, Rituximab 375 mg/m2 at day 1, 4 and 8 and finally caplacizumab 10 mg before the 2nd plasmatic exchange and every day until the ADAMTS13 activity reached over 20%. Antiviral therapy and antibiotics were initiated in Patient 1 and antiviral therapy was maintained in Patient 2. The evolution was promptly favorable with normalization of platelets levels at Day 4 in Patient 1, and Day 15 in Patient 2. Patient 1 stopped caplacizumab at Day 12 and Patient 2 at day 17, when ADAMTS 13 reached over 20%. None of them relapsed after treatment, with a respective follow-up of 4 and 2 months. Conclusion Caplacizumab seems to be a safe and efficient treatment for aTTP in HIV positive patients." @default.
• W3034172868 created "2020-06-12" @default.
• W3034172868 creator A5032927341 @default.
• W3034172868 creator A5054065701 @default.
• W3034172868 creator A5063722807 @default.
• W3034172868 creator A5066032158 @default.
• W3034172868 creator A5088555865 @default.
• W3034172868 creator A5091345735 @default.
• W3034172868 creator A5091610364 @default.
• W3034172868 date "2020-06-01" @default.
• W3034172868 modified "2023-09-30" @default.
• W3034172868 title "P0240ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA IN HIV POSITIVE PATIENTS SUCCESSFULLY TREATED WITH CAPLACIZUMAB: ABOUT TWO CASES" @default.
• W3034172868 doi "https://doi.org/10.1093/ndt/gfaa142.p0240" @default.
• W3034172868 hasPublicationYear "2020" @default.
• W3034172868 type Work @default.
• W3034172868 sameAs 3034172868 @default.
• W3034172868 citedByCount "0" @default.
• W3034172868 crossrefType "journal-article" @default.
• W3034172868 hasAuthorship W3034172868A5032927341 @default.
• W3034172868 hasAuthorship W3034172868A5054065701 @default.
• W3034172868 hasAuthorship W3034172868A5063722807 @default.
• W3034172868 hasAuthorship W3034172868A5066032158 @default.
• W3034172868 hasAuthorship W3034172868A5088555865 @default.
• W3034172868 hasAuthorship W3034172868A5091345735 @default.
• W3034172868 hasAuthorship W3034172868A5091610364 @default.
• W3034172868 hasConcept C126322002 @default.
• W3034172868 hasConcept C203014093 @default.
• W3034172868 hasConcept C2777878052 @default.
• W3034172868 hasConcept C2778258694 @default.
• W3034172868 hasConcept C2778585876 @default.
• W3034172868 hasConcept C2779134260 @default.
• W3034172868 hasConcept C2779338263 @default.
• W3034172868 hasConcept C2779394231 @default.
• W3034172868 hasConcept C2780653079 @default.
• W3034172868 hasConcept C2780921031 @default.
• W3034172868 hasConcept C71924100 @default.
• W3034172868 hasConcept C89560881 @default.
• W3034172868 hasConcept C90924648 @default.
• W3034172868 hasConceptScore W3034172868C126322002 @default.
• W3034172868 hasConceptScore W3034172868C203014093 @default.
• W3034172868 hasConceptScore W3034172868C2777878052 @default.
• W3034172868 hasConceptScore W3034172868C2778258694 @default.
• W3034172868 hasConceptScore W3034172868C2778585876 @default.
• W3034172868 hasConceptScore W3034172868C2779134260 @default.
• W3034172868 hasConceptScore W3034172868C2779338263 @default.
• W3034172868 hasConceptScore W3034172868C2779394231 @default.
• W3034172868 hasConceptScore W3034172868C2780653079 @default.
• W3034172868 hasConceptScore W3034172868C2780921031 @default.
• W3034172868 hasConceptScore W3034172868C71924100 @default.
• W3034172868 hasConceptScore W3034172868C89560881 @default.
• W3034172868 hasConceptScore W3034172868C90924648 @default.
• W3034172868 hasIssue "Supplement_3" @default.
• W3034172868 hasLocation W30341728681 @default.
• W3034172868 hasOpenAccess W3034172868 @default.
• W3034172868 hasPrimaryLocation W30341728681 @default.
• W3034172868 hasRelatedWork W1808843406 @default.
• W3034172868 hasRelatedWork W2066825159 @default.
• W3034172868 hasRelatedWork W2075323718 @default.
• W3034172868 hasRelatedWork W2808596725 @default.
• W3034172868 hasRelatedWork W2945442249 @default.
• W3034172868 hasRelatedWork W2946198964 @default.
• W3034172868 hasRelatedWork W3023971228 @default.
• W3034172868 hasRelatedWork W3033753898 @default.
• W3034172868 hasRelatedWork W3136287829 @default.
• W3034172868 hasRelatedWork W3183528091 @default.
• W3034172868 hasVolume "35" @default.
• W3034172868 isParatext "false" @default.
• W3034172868 isRetracted "false" @default.
• W3034172868 magId "3034172868" @default.
• W3034172868 workType "article" @default.